Trial · NCT01263483
Adverse events33
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 33
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Voglibose 0.2 mg TID | 4 | 75 | |
| other | Nasopharyngitis | Infections and infestations | Alogliptin 12.5 mg QD | 17 | 76 | |
| other | Nasopharyngitis | Infections and infestations | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 13 | 79 | |
| other | Eczema | Skin and subcutaneous tissue disorders | Voglibose 0.2 mg TID | 3 | 75 | |
| other | Eczema | Skin and subcutaneous tissue disorders | Alogliptin 12.5 mg QD | 1 | 76 | |
| other | Eczema | Skin and subcutaneous tissue disorders | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0 | 79 | |
| serious | Osteomyelitis | Infections and infestations | Voglibose 0.2 mg TID | 1 | 75 | |
| serious | Osteomyelitis | Infections and infestations | Alogliptin 12.5 mg QD | 0 | 76 | |
| serious | Osteomyelitis | Infections and infestations | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0 | 79 | |
| serious | Pneumonia | Infections and infestations | Voglibose 0.2 mg TID | 1 | 75 | |
| serious | Pneumonia | Infections and infestations | Alogliptin 12.5 mg QD | 0 | 76 | |
| serious | Pneumonia | Infections and infestations | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 1 | 79 | |
| serious | Pyelonephritis acute | Infections and infestations | Voglibose 0.2 mg TID | 1 | 75 | |
| serious | Pyelonephritis acute | Infections and infestations | Alogliptin 12.5 mg QD | 0 | 76 | |
| serious | Pyelonephritis acute | Infections and infestations | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0 | 79 | |
| serious | Cerebral infarction | Nervous system disorders | Voglibose 0.2 mg TID | 1 | 75 | |
| serious | Cerebral infarction | Nervous system disorders | Alogliptin 12.5 mg QD | 0 | 76 | |
| serious | Cerebral infarction | Nervous system disorders | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0 | 79 | |
| serious | Acute myocardial infarction | Cardiac disorders | Voglibose 0.2 mg TID | 1 | 75 | |
| serious | Acute myocardial infarction | Cardiac disorders | Alogliptin 12.5 mg QD | 0 | 76 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01263483/events